Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or ?lot? of Intravenous Immunoglobulin. Scope of the Report: This report focuses on the Intravenous Immunoglobulin (IVIg) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. North America region is the largest supplier of intravenous immunoglobulin (IVIg), with a production market share nearly 48% in 2016. Europe is the second largest supplier of intravenous immunoglobulin (IVIg), enjoying production market share nearly 23% in 2016. North America is the largest sales place, with a sales market share nearly 44% in 2016. Following North America, Europe is the second largest sales place with the sales market share of 22%. Market competition is intense. Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry. The worldwide market for Intravenous Immunoglobulin (IVIg) is expected to grow at a CAGR of roughly 6.0% over the next five years, will reach 11500 million US$ in 2023, from 8120 million US$ in 2017, according to a new GIR (Global Info Research) study. Market Segment by Manufacturers, this report covers Baxter Grifols CSL Octapharma Biotest Kedrion Hualan Bio CNBG Shanghai RAAS CBPO LFB Group BPL Sichuan Yuanda Shuyang Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Type, covers IVIg Liquid IVIg Powder Market Segment by Applications, can be divided into Immunodeficiency Autoimmune Disease Acute Infection There are 15 Chapters to deeply display the global Intravenous Immunoglobulin (IVIg) market. Chapter 1 to describe Intravenous Immunoglobulin (IVIg) Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of Intravenous Immunoglobulin (IVIg), with sales, revenue, and price of Intravenous Immunoglobulin (IVIg), in 2016 and 2017; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of Intravenous Immunoglobulin (IVIg), for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions; Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018; Chapter 12, Intravenous Immunoglobulin (IVIg) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023; Chapter 13, 14 and 15, to describe Intravenous Immunoglobulin (IVIg) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Table of Contents 1 Market Overview 1.1 Intravenous Immunoglobulin (IVIg) Introduction 1.2 Market Analysis by Type 1.2.1 IVIg Liquid 1.2.2 IVIg Powder 1.3 Market Analysis by Applications 1.3.1 Immunodeficiency 1.3.2 Autoimmune Disease 1.3.3 Acute Infection 1.4 Market Analysis by Regions 1.4.1 North America (United States,
